Aviance Capital Partners LLC Has $6.98 Million Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Aviance Capital Partners LLC increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.2% during the first quarter, HoldingsChannel.com reports. The firm owned 14,019 shares of the medical research company’s stock after buying an additional 437 shares during the period. Thermo Fisher Scientific accounts for about 1.0% of Aviance Capital Partners LLC’s investment portfolio, making the stock its 20th largest holding. Aviance Capital Partners LLC’s holdings in Thermo Fisher Scientific were worth $6,976,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the company. One Charles Private Wealth Services LLC increased its position in shares of Thermo Fisher Scientific by 4.2% during the fourth quarter. One Charles Private Wealth Services LLC now owns 499 shares of the medical research company’s stock valued at $260,000 after purchasing an additional 20 shares during the period. Revolve Wealth Partners LLC grew its position in Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after acquiring an additional 20 shares during the period. Holderness Investments Co. grew its position in Thermo Fisher Scientific by 1.7% in the fourth quarter. Holderness Investments Co. now owns 1,277 shares of the medical research company’s stock valued at $664,000 after acquiring an additional 21 shares during the period. Port Capital LLC grew its position in Thermo Fisher Scientific by 1.6% in the fourth quarter. Port Capital LLC now owns 1,385 shares of the medical research company’s stock valued at $721,000 after acquiring an additional 22 shares during the period. Finally, Clark Capital Management Group Inc. grew its position in Thermo Fisher Scientific by 0.5% in the fourth quarter. Clark Capital Management Group Inc. now owns 4,445 shares of the medical research company’s stock valued at $2,312,000 after acquiring an additional 23 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on TMO shares. Scotiabank lowered their price target on Thermo Fisher Scientific from $650.00 to $605.00 and set a “sector perform” rating on the stock in a research report on Friday, April 25th. Barclays decreased their target price on Thermo Fisher Scientific from $475.00 to $450.00 and set an “equal weight” rating on the stock in a report on Tuesday, June 24th. Royal Bank Of Canada decreased their target price on Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating on the stock in a report on Thursday, April 24th. Argus decreased their target price on Thermo Fisher Scientific from $620.00 to $470.00 and set a “buy” rating on the stock in a report on Tuesday, April 29th. Finally, UBS Group decreased their target price on Thermo Fisher Scientific from $715.00 to $500.00 and set a “buy” rating on the stock in a report on Thursday, April 24th. Four equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $604.05.

Insider Activity

In other news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction on Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the sale, the executive vice president owned 23,167 shares of the company’s stock, valued at $9,960,188.31. This represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Trading Up 0.1%

TMO opened at $428.25 on Friday. The firm’s fifty day moving average is $409.10 and its two-hundred day moving average is $480.59. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.38 and a current ratio of 1.77. The firm has a market cap of $161.66 billion, a PE ratio of 25.12, a price-to-earnings-growth ratio of 2.27 and a beta of 0.77. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 15.19% and a return on equity of 17.15%. The company had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. During the same period last year, the business posted $5.11 earnings per share. The business’s revenue for the quarter was up .2% compared to the same quarter last year. Equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.40%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific’s dividend payout ratio is 10.09%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.